https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-07-01 / Cancer 2014 Nov;120(21):3418-25
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-07-01 / Cancer 2014 Nov;120(21):3418-252014-07-01 00:00:002014-07-01 00:00:00Noninvasive radiofrequency treatment effect on mitochondria in pancreatic cancer cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-05-30 / J Clin Oncol 32, 2014 (suppl; abstr e15254)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-05-30 / J Clin Oncol 32, 2014 (suppl; abstr e15254)2014-05-30 00:00:002014-05-30 00:00:00A feasibility and safety study of vaccination with poly-ICLC and peptide-pulsed dendritic cells in patients with metastatic, locally advanced unresectable, or recurrent pancreatic adenocarcinoma.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-04-29 / Cancer Immunol. Immunother. 2014 Aug;63(8):797-806
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-04-29 / Cancer Immunol. Immunother. 2014 Aug;63(8):797-8062014-04-29 00:00:002019-02-15 08:52:30Prognostic factors related to add-on dendritic cell vaccines on patients with inoperable pancreatic cancer receiving chemotherapy: a multicenter analysis
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-01-03 / Cancer Gene Ther. 2014 Jan;21(1):24-30
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-01-03 / Cancer Gene Ther. 2014 Jan;21(1):24-302014-01-03 00:00:002014-01-03 00:00:00Different responses of human pancreatic adenocarcinoma cell lines to oncolytic Newcastle disease virus infection
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-06-03 / J Clin Oncol 31, 2013 (suppl; abstr 3049)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-06-03 / J Clin Oncol 31, 2013 (suppl; abstr 3049)2013-06-03 00:00:002013-06-03 00:00:00Phase II study of dendritic cell vaccination combined with recombinant adenovirus-p53 in treatment for patients with advanced pancreatic carcinoma.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-04-19 / Cancer Immunol. Immunother. 2013 Jun;62(6):1083-91
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-04-19 / Cancer Immunol. Immunother. 2013 Jun;62(6):1083-912013-04-19 00:00:002019-02-15 08:52:30Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-12-17 / Int J Hyperthermia 2013;29(1):8-16
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-12-17 / Int J Hyperthermia 2013;29(1):8-162012-12-17 00:00:002012-12-17 00:00:00Gemcitabine and cisplatin combined with regional hyperthermia as second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-09-10 / JOP 2012 Sep;13(5):502-13
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-09-10 / JOP 2012 Sep;13(5):502-132012-09-10 00:00:002012-09-10 00:00:00Two avirulent, lentogenic strains of Newcastle disease virus are cytotoxic for some human pancreatic tumor lines in vitro
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-08-01 / J. Cell. Mol. Med. 2012 Aug;16(8):1776-91
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-08-01 / J. Cell. Mol. Med. 2012 Aug;16(8):1776-912012-08-01 00:00:002012-08-01 00:00:00Heat shock protein 27 as a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2012-07-27 / Int J Hyperthermia 2012;28(7):597-604
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2012-07-27 / Int J Hyperthermia 2012;28(7):597-6042012-07-27 00:00:002012-07-27 00:00:00Phase II trial of combined regional hyperthermia and gemcitabine for locally advanced or metastatic pancreatic cancer
